Stephane Bancel - 26 Feb 2026 Form 3 Insider Report for Generate Biomedicines, Inc. (GENB)

Role: Director
Signature: /s/ Michael Wolf, Attorney-in-Fact
Issuer symbol: GENB
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 26 Feb 2026, 20:41:50 UTC
Previous filing: 13 Feb 2026
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bancel Stephane	Director	GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE	/s/ Michael Wolf, Attorney-in-Fact	26 Feb 2026	0001443340

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	GENB	Common Stock						460,829	26 Feb 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	GENB	Series A Preferred Stock							26 Feb 2026	Common Stock	724,160		By OCHA LLC	F1, F2
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	32,916	$6.10	Direct	F3
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	32,916	$7.25	Direct	F4
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	32,916	$9.15	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2	Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-1.5190 basis at the option of the holder, and will convert automatically upon the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
F3	The shares underlying this option vest in sixteen equal quarterly installments following March 1, 2023, subject to the Reporting Person's continued service on each such vesting date.
F4	The shares underlying this option vest in sixteen equal quarterly installments following February 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F5	The shares underlying this option vest in sixteen equal quarterly installments following February 1, 2025, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney